​

Acrivon Therapeutics (ACRV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ACRV Stock Forecast

Acrivon Therapeutics (ACRV) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $21.83, with a high of $30.00 and a low of $17.00. This represents a 1055.03% increase from the last price of $1.89.

- $6 $12 $18 $24 $30 High: $30 Avg: $21.83 Low: $17 Last Closed Price: $1.89

ACRV Stock Rating

Acrivon Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

ACRV Price Target Upside V Benchmarks

TypeNameUpside
StockAcrivon Therapeutics1055.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.89$1.89$1.89
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26351--9
Dec, 25351--9
Nov, 25441--9
Oct, 25441--9
Sep, 25441--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 14, 2024Etzer DaroutBMO Capital$27.00$7.92240.91%1328.57%
Sep 16, 2024Etzer DaroutBMO Capital$28.00$8.91214.25%1381.48%
Aug 13, 2024Matthew BieglerOppenheimer$18.00$7.26147.93%852.38%
May 14, 2024Matthew BieglerOppenheimer$21.00$8.36151.20%1011.11%
May 14, 2024Emily BodnarH.C. Wainwright$22.00$8.35163.47%1064.02%
May 14, 2024Etzer DaroutBMO Capital$25.00$8.51193.77%1222.75%
Apr 25, 2024Joseph CatanzaroPiper Sandler$30.00$9.20226.09%1487.30%
Apr 25, 2024Silvan TuerkcanJMP Securities$17.00$9.5078.95%799.47%
Mar 28, 2024Emily BodnarH.C. Wainwright$20.00$7.19178.16%958.20%
Dec 12, 2022Jefferies$17.00$12.5036.00%799.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 09, 2026Piper SandlerOverweightOverweighthold
Jan 31, 2025Cantor FitzgeraldOverweightinitialise
Nov 14, 2024BMO CapitalOutperformOutperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024BMO CapitalOutperformOutperformhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Aug 14, 2024BMO CapitalOutperformOutperformhold
Aug 13, 2024OppenheimerOutperformOutperformhold
May 14, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.74$-0.24----
Avg Forecast$-2.62$-2.52$-2.82$-2.74$-2.25$-0.93
High Forecast$-2.50$-2.36$-2.22$-1.90$-0.90$-0.93
Low Forecast$-2.83$-2.72$-3.46$-3.51$-4.86$-0.93
Surprise %4.58%-90.48%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$716.11K$19.96M$79.99M$171.76M
High Forecast--$716.11K$19.96M$83.59M$171.76M
Low Forecast--$716.11K$19.96M$76.39M$171.76M
Surprise %------

Net Income Forecast

$-110M $-91M $-72M $-53M $-34M $-15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-60.39M$-80.56M----
Avg Forecast$-60.39M$-56.08M$-62.75M$-59.71M$-63.65M$-20.62M
High Forecast$-55.27M$-52.09M$-49.02M$-41.94M$-19.92M$-20.62M
Low Forecast$-62.54M$-60.07M$-76.47M$-77.49M$-107.37M$-20.62M
Surprise %-43.64%----

ACRV Forecast FAQ

Is Acrivon Therapeutics stock a buy?

Acrivon Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Acrivon Therapeutics is a favorable investment for most analysts.

What is Acrivon Therapeutics's price target?

Acrivon Therapeutics's price target, set by 10 Wall Street analysts, averages $21.83 over the next 12 months. The price target range spans from $17 at the low end to $30 at the high end, suggesting a potential 1055.03% change from the previous closing price of $1.89.

How does Acrivon Therapeutics stock forecast compare to its benchmarks?

Acrivon Therapeutics's stock forecast shows a 1055.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Acrivon Therapeutics over the past three months?

  • January 2026: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 44.44% Strong Buy, 44.44% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Acrivon Therapeutics’s EPS forecast?

Acrivon Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.82, marking a 1075.00% increase from the reported $-0.24 in 2024. Estimates for the following years are $-2.74 in 2026, $-2.25 in 2027, and $-0.93 in 2028.

What is Acrivon Therapeutics’s revenue forecast?

Acrivon Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $716.11K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $19.96M, followed by $79.99M for 2027, and $171.76M for 2028.

What is Acrivon Therapeutics’s net income forecast?

Acrivon Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-62.745M, representing a -22.11% decrease from the reported $-80.556M in 2024. Projections indicate $-59.715M in 2026, $-63.645M in 2027, and $-20.621M in 2028.